Engineering customized nanovaccines for enhanced cancer immunotherapy

Guo, Jinyu; Liu, Changhua; Qi, Zhaoyang; Qiu, Ting; Zhang, Jin; Yang, Huanghao

doi:10.1016/j.bioactmat.2024.02.028

Cited by 3 publications

(1 citation statement)

References 259 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although excellent reviews on requirements for successful nanovaccines for cancer immunotherapy are available [193,194], just a few high-light emerging cationic nanovaccines [14,78,185,192,195]. During the past decades, cationic lipids or polymers in NPs have shown superior immunostimulatory properties as compared to their neutral and anionic analogues and recognized as potent inducers of antigen-specific T-cells; cationic NPs have offered clinically applicable vaccine formulation platforms [78].…”

Section: Cationic Nanostructures In Vaccine Design Against Cancermentioning

confidence: 99%

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Preprint

View full text Add to dashboard Cite

Nanovaccines are able to deliver antigen(s) and immunomodulator(s) directly to antigen-presenting cells (APCs) of the lymphatic system. Positive charges improve their uptake by APCs and often drive a Th-1 biased immune response so necessary against infectious diseases caused by intracellular pathogens and cancers. However, cationic compounds often display a dose-dependent toxicity so that systematic evaluation of cytotoxicity against cells in culture is required. After the rapid evolution of nanovaccines against SARS-Covid 2, mRNA vaccines gained much strength and have been designed against several infectious diseases, often relying on cationic components for mRNA protection. Once established the limiting concentration for the cationic compound, cationic nanovaccines perform well eliciting the desired Th-1 improved immune response in most cases. Other valuable approach found in the literature has been the construction of biocompatible nanoparticles (NPs) carrying cationic lipids, polymers or surfactants so that minimization of the concentration for the cationic component led to absence of toxicity. Against cancer, recent constructions of nanovaccines in situ after cancer cell disruption in the presence of adjuvants led to systemic presentation of multiple tumoral antigens yielding, in many instances, prevention of metastasis appearance and conversion of tumors non treatable by immunotherapy into treatable ones.

show abstract